0000000000600003
AUTHOR
Maria Picciotto
Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis
Nivolumab (N) is a novel therapeutic option in NSCLC, with a significant survival gain compared with Docetaxel (D). However, predictive biomarkers are lacking and no strategies have been adopted to date for optimal patients (pts) selection. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response in pts treated with N or D.
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer
Pemetrexed has been widely used in patients with advanced non-small cell lung cancer (NSCLC). The clinical relevance of polymorphisms of folate pathway genes for pemetrexed metabolism have not been fully elucidated yet. The aim of this study was to evaluate the expression levels of circulating miR-22, miR-24, and miR-34a, possibly involved in folate pathway, in NSCLC patients treated with pemetrexed compared with healthy controls and to investigate their impact on patient clinical outcomes. A total of 22 consecutive patients with advanced NSCLC, treated with pemetrexed-based chemotherapy and 27 age and sex matched healthy controls were included in this preliminary analysis. miR-22, miR-24, …